<DOC>
	<DOCNO>NCT02802306</DOCNO>
	<brief_summary>This Outside United States , post-CE Mark , multi-center , single-arm , non-blinded study design investigate safety efficacy Tack Endovascular System . This study evaluate subject PAD receive PTA ( drug-coated balloon ( DCB ) ) SFA popliteal artery , range diameter 2.5mm 6.0mm lesion length ≥20mm ≤150mm , result dissection ( ) type ( ) A F. TOBA III also evaluate safety efficacy device use treat sub-group presenting long lesion &gt; 150mm ≤250mm .</brief_summary>
	<brief_title>Tack Optimized Drug Coated Balloon Angioplasty Study Tack Endovascular System™ Femoropoliteal Arteries</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Subject must meet follow inclusion criterion eligible enrollment : 1 . Male nonpregnant Female ≥ 18 year age time consent 2 . Female subject childbearing potential must negative pregnancy test prior treatment must use form contraception duration study 3 . Target limb require additional treatment aside target lesion iliac artery ( y ) index procedure 4 . Subject inform understands nature study provide sign informed consent participate study . If subject posse ability understand provide inform consent due physical inability , subject sign ICF , impartial witness may sign behalf subject 5 . Willing comply require followup visit 6 . Rutherford Classification 2 , 3 4 7 . Estimated life expectancy &gt; 1 year 8 . Eligible standard surgical repair , necessary 9 . Subject ambulatory ( assistive device cane walker acceptable Subject must NOT meet follow exclusion criterion eligible enrollment : 1 . Rutherford Classification 0 , 1 , 5 6 2 . Is pregnant refuse use contraception duration study 3 . Previous infrainguinal bypass graft target limb 4 . Planned amputation target limb 5 . Systemic infection infection within target limb and/or immunocompromised 6 . Endovascular surgical procedure ( include diagnostic procedure ) target limb within 30 day prior within 30 day index procedure 7 . Endovascular surgical procedure ( include diagnostic procedure ) nontarget limb within 14 day prior index procedure plan procedure within 30 day index procedure 8 . Prior coronary artery bypass graft ( CABG ) percutaneous coronary intervention ( PCI ) procedure within 30 day prior index procedure plan CABG/PCI within 30 day index procedure 9 . Any previous planned surgical endovascular procedure ( include diagnostic procedure ) within 14 day prior 30 day post index procedure 10 . Planned atherectomy , cryoplasty , stenting treatment ( exception cross device ) target lesion PTA index procedure 11 . Known coagulopathy , hypercoagulable state , bleed diathesis , blood disorder , platelet count le 80,000/microliter great 500,000/microliter 12 . Known hypersensitivity allergy antiplatelet anticoagulant therapy 13 . Myocardial infarction within 30 day prior enrollment 14 . History stroke within 90 day prior enrollment 15 . Serum creatinine &gt; 2.5 mg/dL 16 . Requires treatment tibial outflow vessel index procedure , include P2 P3 segment popliteal artery tibioperoneal vessel 17 . Known hypersensitivity contraindication nickeltitanium alloy ( Nitinol ) 18 . Participating another ongoing investigational clinical trial complete primary endpoint 19 . Has comorbidities , opinion investigator , would preclude receive treatment and/or participate studyrequired followup assessment 20 . Known hypersensitivity allergy contrast agent medically manage 21 . Thrombolysis target vessel within 72 hour prior index procedure , complete resolution thrombus achieve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Angioplasty</keyword>
	<keyword>Peripheral Artery Disease</keyword>
	<keyword>PAD</keyword>
	<keyword>Lesion</keyword>
	<keyword>Claudication</keyword>
</DOC>